Syngene Gears For Biologics Build Up

Syngene, one of Asia's largest contract research organizations, has reported strong first quarter numbers and is bolstering its biologics services business with a new viral testing facility. Brexit isn't a "structural event" for Syngene and the CRO's top brass also outlines to Scrip the significant cost advantage that the firm offers over Chinese and Western competitors.

Syngene International Ltd reported a 23% increase in revenues for the first quarter ended June to INR2.90bn ($43m), buoyed by robust growth in its discovery services and development and manufacturing services verticals. Net profits for the quarter were up 28% to INR600m.

"From a revenue perspective Q1 was pleasing and gives us a robust platform for the rest of the year. We...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip